Patiromer in the Heart Failure Subgroup of the AMBER Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Heart Failure
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patiromer Versus Placebo to Enable Spironolactone Use in Patients With Resistant Hypertension and Chronic Kidney Disease (AMBER): Results in the Pre-Specified Subgroup With Heart Failure
Eur. J. Heart Fail 2020 May 25;[EPub Ahead of Print], P Rossignol, B Williams, MR Mayo, S Warren, S Arthur, G Ackourey, WB White, R AgarwalFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.